Search Results - "WIKLUND, Olov"

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel by Borén, Jan, Chapman, M John, Krauss, Ronald M, Packard, Chris J, Bentzon, Jacob F, Binder, Christoph J, Daemen, Mat J, Demer, Linda L, Hegele, Robert A, Nicholls, Stephen J, Nordestgaard, Børge G, Watts, Gerald F, Bruckert, Eric, Fazio, Sergio, Ference, Brian A, Graham, Ian, Horton, Jay D, Landmesser, Ulf, Laufs, Ulrich, Masana, Luis, Pasterkamp, Gerard, Raal, Frederick J, Ray, Kausik K, Schunkert, Heribert, Taskinen, Marja-Riitta, van de Sluis, Bart, Wiklund, Olov, Tokgozoglu, Lale, Catapano, Alberico L, Ginsberg, Henry N

“…Abstract…”
Get full text

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel by Ference, Brian A, Ginsberg, Henry N, Graham, Ian, Ray, Kausik K, Packard, Chris J, Bruckert, Eric, Hegele, Robert A, Krauss, Ronald M, Raal, Frederick J, Schunkert, Heribert, Watts, Gerald F, Borén, Jan, Fazio, Sergio, Horton, Jay D, Masana, Luis, Nicholls, Stephen J, Nordestgaard, Børge G, van de Sluis, Bart, Taskinen, Marja-Riitta, Tokgözoglu, Lale, Landmesser, Ulf, Laufs, Ulrich, Wiklund, Olov, Stock, Jane K, Chapman, M John, Catapano, Alberico L

“…To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD). We assessed whether…”
Get full text

Statin use and non-alcoholic steatohepatitis in at risk individuals by Dongiovanni, Paola, Petta, Salvatore, Mannisto, Ville, Mancina, Rosellina Margherita, Pipitone, Rosaria, Karja, Vesa, Maggioni, Marco, Kakela, Pirjo, Wiklund, Olov, Mozzi, Enrico, Grimaudo, Stefania, Kaminska, Dorota, Rametta, Raffaela, Craxi, Antonio, Fargion, Silvia, Nobili, Valerio, Romeo, Stefano, Pihlajamaki, Jussi, Valenti, Luca

“…Graphical abstract…”
Get full text

The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent by Mancina, Rosellina Margherita, Dongiovanni, Paola, Petta, Salvatore, Pingitore, Piero, Meroni, Marica, Rametta, Raffaela, Borén, Jan, Montalcini, Tiziana, Pujia, Arturo, Wiklund, Olov, Hindy, George, Spagnuolo, Rocco, Motta, Benedetta Maria, Pipitone, Rosaria Maria, Craxì, Antonio, Fargion, Silvia, Nobili, Valerio, Käkelä, Pirjo, Kärjä, Vesa, Männistö, Ville, Pihlajamäki, Jussi, Reilly, Dermot F, Castro-Perez, Jose, Kozlitina, Julia, Valenti, Luca, Romeo, Stefano

“…Background & Aims Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver damage and is characterized by steatosis. Genetic factors increase risk…”
Get full text

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM by Langlois, Michel R, Chapman, M John, Cobbaert, Christa, Mora, Samia, Remaley, Alan T, Ros, Emilio, Watts, Gerald F, Borén, Jan, Baum, Hannsjörg, Bruckert, Eric, Catapano, Alberico, Descamps, Olivier S, von Eckardstein, Arnold, Kamstrup, Pia R, Kolovou, Genovefa, Kronenberg, Florian, Langsted, Anne, Pulkki, Kari, Rifai, Nader, Sypniewska, Grazyna, Wiklund, Olov, Nordestgaard, Børge G

“…The European Atherosclerosis Society-European Federation of Clinical Chemistry and Laboratory Medicine Consensus Panel aims to provide recommendations to…”
Get full text

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk by Landmesser, Ulf, Chapman, M. John, Farnier, Michel, Gencer, Baris, Gielen, Stephan, Hovingh, G Kees, Lüscher, Thomas F, Sinning, David, Tokgözoglu, Lale, Wiklund, Olov, Zamorano, Jose Luis, Pinto, Fausto J, Catapano, Alberico L

Get full text

Induction of proinflammatory cytokines by long-chain saturated fatty acids in human macrophages by Håversen, Liliana, Danielsson, Kristina Norén, Fogelstrand, Linda, Wiklund, Olov

“…Abstract Increased circulating free fatty acids in subjects with type 2 diabetes may contribute to activation of macrophages, and thus the development of…”
Get full text

Patatin-like phospholipase domain-containing 3 ( PNPLA3 ) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro by Pirazzi, Carlo, Adiels, Martin, Burza, Maria Antonella, Mancina, Rosellina Margherita, Levin, Malin, Ståhlman, Marcus, Taskinen, Marja-Riitta, Orho-Melander, Marju, Perman, Jeanna, Pujia, Arturo, Andersson, Linda, Maglio, Cristina, Montalcini, Tiziana, Wiklund, Olov, Borén, Jan, Romeo, Stefano

“…Background & Aims The robust association between non-alcoholic fatty liver disease (NAFLD) and the genetic variant I148M (rs738409) in PNPLA3 has been widely…”
Get full text

Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy by Wiklund, Olov, Pirazzi, Carlo, Romeo, Stefano

“…A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are…”
Get full text

Subendothelial retention of atherogenic lipoproteins in early atherosclerosis by Borén, Jan, Skålén, Kristina, Gustafsson, Maria, Rydberg, Ellen Knutsen, Hultén, Lillemor Mattsson, Wiklund, Olov, Innerarity, Thomas L

“…Complications of atherosclerosis are the most common cause of death in Western societies. Among the many risk factors identified by epidemiological studies,…”
Get full text

ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan by HIUKKA, Anne, STAHLMAN, Marcus, OLOFSSON, Sven-Olof, TASKINEN, Marja-Riitta, EKROOS, Kim, BOREN, Jan, PETTERSSON, Camilla, LEVIN, Malin, ADIELS, Martin, TENEBERG, Susanne, LEINONEN, Eeva S, HULTEN, Lillemor Mattsson, WIKLUND, Olov, ORESIC, Matej

“…ApoCIII-Enriched LDL in Type 2 Diabetes Displays Altered Lipid Composition, Increased Susceptibility for Sphingomyelinase, and Increased Binding to Biglycan…”
Get full text

Arachidonate 15-lipoxygenase type B knockdown leads to reduced lipid accumulation and inflammation in atherosclerosis by Magnusson, Lisa U, Lundqvist, Annika, Karlsson, Merja Nurkkala, Skålén, Kristina, Levin, Max, Wiklund, Olov, Borén, Jan, Hultén, Lillemor Mattsson

“…Inflammation in the vascular wall is important for development of atherosclerosis. We have shown previously that arachidonate 15-lipoxygenase type B (ALOX15B)…”
Get full text

ATP depletion in macrophages in the core of advanced rabbit atherosclerotic plaques in vivo by Leppänen, Olli, Björnheden, Tom, Evaldsson, Margareta, Borén, Jan, Wiklund, Olov, Levin, Max

“…The cores of rabbit plaques in vivo are hypoxic, suggesting that ATP depletion due to an insufficient supply of oxygen and nutrients could contribute to…”
Get full text

In Memoriam: Sven-Olof Olofsson (1947-2011)1 by Borén, Jan, Bondjers, Göran, Wiklund, Olov

Get full text

Long-Term Effects of Fenofibrate on Carotid Intima-Media Thickness and Augmentation Index in Subjects With Type 2 Diabetes Mellitus by Hiukka, Anne, MD, Westerbacka, Jukka, MD, PhD, Leinonen, Eeva S., MD, PhD, Watanabe, Hiroshi, MD, PhD, Wiklund, Olov, MD, PhD, Hulten, Lillemor Mattson, PhD, Salonen, Jukka T., DMedSc, Tuomainen, Tomi-Pekka, MD, PhD, Yki-Järvinen, Hannele, MD, PhD, Keech, Anthony C., MD, PhD, Taskinen, Marja-Riitta, MD, PhD

“…Objectives The aim of this substudy was to ascertain whether long-term treatment with fenofibrate reduces surrogate measures of atherosclerosis, biomarkers of…”
Get full text

Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease by Olofsson, Sven-Olof, Wiklund, Olov, Borén, Jan

“…Apolipoprotein (apo) AI and apoB are the major apolipoproteins of high-density lipoprotein (HDL) and low-density lipoprotein (LDL), respectively. ApoB…”
Get full text

2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk by Mach, Francois, Baigent, Colin, Catapano, Alberico L., Koskinas, Konstantinos C., Casula, Manuela, Badimon, Lina, Chapman, M. John, De Backer, Guy G., Delgado, Victoria, Ference, Brian A., Graham, Ian M., Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R., Riccardi, Gabriele, Richter, Dimitrios J., Sabatine, Marc S., Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov

“…The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)…”
Get full text

Antibodies to Oxidized LDL in Relation to Carotid Atherosclerosis, Cell Adhesion Molecules, and Phospholipase A2 by Hulthe, Johannes, Wiklund, Olov, Hurt-Camejo, Eva, Bondjers, Göran

“…Abstract —The role of the humoral immune response to oxidized low density lipoprotein (Ox-LDL) in atherogenesis is unclear and available studies are…”
Get full text

German Camejo (1936–2021) by Wiklund, Olov, Bondjers, Göran

Get full text

Major role of HSP70 as a paracrine inducer of cytokine production in human oxidized LDL treated macrophages by Svensson, Per-Arne, Asea, Alexzander, Englund, Mikael C.O., Bausero, Maria A., Jernås, Margareta, Wiklund, Olov, Ohlsson, Bertil G., Carlsson, Lena M.S., Carlsson, Björn

“…Lipid accumulation and inflammation are key hallmarks of the atherosclerotic plaque and macrophage uptake of oxidized low-density lipoprotein (oxLDL) is…”
Get full text